Lung cancer, non-small cell: Treatment - Health Professional Information [NCI PDQ] - Quest Diagnostics Patient Health Library The median progression-free survival was 2.23 months versus 1.84 months (HR = 0.6; 95% CI, 0.51-0.73; P-.001).[ 18 ][Level of evidence: 1iiA] When used in combination with carboplatin/paclitaxel [ 19 ] or cisplatin/gemcitabine, [ 20 ] erlotinib was not found to improve response rates, progression-free survival, or overall survival in previously untreated patients with advanced or...
Gefitinib - [Medication] - Quest Diagnostics Patient Health Library Gefitinib Examples Brand Name Chemical Name Iressa gefitinib How It Works Gefitinib is an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TK) that blocks growth factors that allow some tumors to grow.Gefitinib ...
A to Z List - Medication Information Jude Children's Research Hospital.- Disclaimer / Registrations / Copyright Statement - Privacy Policy - Notice of Privacy Practices - Linking Policy - Help A to Z List - Medication Information A to Z List - Medication Information abacavir, lamivudine, zidovudine, trizivir, acyclovir, allopurinol, amifostine, amitriptyline, amlodipine, amoxicillin, clavulanic_acid, augmentin,...
author: St. Jude Children's Research Hospital
ASTRAZENECA TO START PHASE III TRIALS WITH ZACTIMA TM (ZD6474) a€“ A NOVEL TARGETED LUNG CANCER TREATMENT Skip to content Home Media Press releases - 2005 - 2004 - 2003 - 2002 - 2001 - 2000 - 1999 - 1998 Corporate reports Facts, products, pipeline Image library Events calendar Media contacts Investors Careers Products Licensing Research Responsibility About us Contact us Home - - Media - -Press releases - - function managePressContacts() { window.navigate("ncm.aspx?node=press"); }...
GEFITINIB (IRESSA) MARKETING AUTHORISATION APPLICATION WITHDRAWN IN EU Skip to content Home Media Press releases - 2005 - 2004 - 2003 - 2002 - 2001 - 2000 - 1999 - 1998 Corporate reports Facts, products, pipeline Image library Events calendar Media contacts Investors Careers Products Licensing Research Responsibility About us Contact us Home - - Media - -Press releases - - function managePressContacts() { window.navigate("ncm.aspx?node=press"); }...
GEFITINIB (IRESSA) LUNG CANCER ISEL TRIAL INFORMATION Skip to content Home Media Press releases - 2005 - 2004 - 2003 - 2002 - 2001 - 2000 - 1999 - 1998 Corporate reports Facts, products, pipeline Image library Events calendar Media contacts Investors Careers Products Licensing Research Responsibility About us Contact us Home - - Media - - Press releases - -2004 - - function managePressContacts() { window.navigate("ncm.aspx?node=press");...
AstraZeneca News - press release archive - pharmaceutical news - 2004 Skip to content Home Media Press releases - 2005 - 2004 - 2003 - 2002 - 2001 - 2000 - 1999 - 1998 Corporate reports Facts, products, pipeline Image library Events calendar Media contacts Investors Careers Products Licensing Research Responsibility About us Contact us Home - - Media - - Press releases - -2004 - - Press release archive 2004 27 December 2004 COUNCIL RECOMMENDS APPROVAL...
AstraZeneca International - pharmaceutical company, prescription drugs, medicine manufacturers Skip to content Home Media Investors Careers Products Licensing Research Responsibility About us Contact us - - Iressa (gefitinib, ZD1839) Iressa (gefitinib, ZD1839) has recently been approved by the Food and Drug Administration in in Argentina, Korea and Singapore-for the treatment of advanced non-small-cell lung cancer (NSCLC).
AstraZeneca International - pharmaceutical company, prescription drugs, medicine manufacturers Skip to content Home Media Investors Careers Products Licensing Research Responsibility About us Contact us - - Oncology Over 12 million people are diagnosed with cancer each year, and it is predicted to be the leading cause of death in the US by 2005.
AstraZeneca Products - Drug information, prescription medicines, pharmaceuticals Skip to content Home Media Investors Careers Products Cardiovascular Gastrointestinal Infection Neuroscience Oncology Respiratory Non pharma businesses Licensing Research Responsibility About us Contact us Home - -Products - - Products Our skills and resources are concentrated on six important areas of healthcare - representing the majority of the worldwide burden of disease.
ASTRAZENECA SECURES FIRST MARKET APPROVAL FOR IRESSAa„¢ IN JAPAN Skip to content Home Media Press releases - 2005 - 2004 - 2003 - 2002 - 2001 - 2000 - 1999 - 1998 Corporate reports Facts, products, pipeline Image library Events calendar Media contacts Investors Careers Products Licensing Research Responsibility About us Contact us Home - - Media - - Press releases - -2002 - - function managePressContacts() { window.navigate("ncm.aspx?node=press");...
ASTRAZENECA ANNOUNCES FDA REQUIRES MORE TIME FOR REVIEW OF IRESSA (ZD1839) U.S. APPLICATION Skip to content Home Media Press releases - 2005 - 2004 - 2003 - 2002 - 2001 - 2000 - 1999 - 1998 Corporate reports Facts, products, pipeline Image library Events calendar Media contacts Investors Careers Products Licensing Research Responsibility About us Contact us Home - - Media - - Press releases - -2003 - - function managePressContacts() { window.navigate("ncm.aspx?node=press");...
ASTRAZENECA SUBMITS IRESSA (gefitinib, ZD1839) FOR APPROVAL IN EUROPE FOR ADVANCED NON-SMALL CELL LUNG CANCER Skip to content Home Media Press releases - 2005 - 2004 - 2003 - 2002 - 2001 - 2000 - 1999 - 1998 Corporate reports Facts, products, pipeline Image library Events calendar Media contacts Investors Careers Products Licensing Research Responsibility About us Contact us Home - - Media - - Press releases - -2003 - - function managePressContacts() { window.navigate("ncm.aspx?node=press");...
ASTRAZENECA RECEIVES AUSTRALIAN APPROVAL FOR IRESSA FOR ADVANCED NON-SMALL CELL LUNG CANCER Skip to content Home Media Press releases - 2005 - 2004 - 2003 - 2002 - 2001 - 2000 - 1999 - 1998 Corporate reports Facts, products, pipeline Image library Events calendar Media contacts Investors Careers Products Licensing Research Responsibility About us Contact us Home - - Media - - Press releases - -2003 - - function managePressContacts() { window.navigate("ncm.aspx?node=press");...
ASTRAZENECA RECEIVES FDA APPROVAL FOR NEW CANCER DRUG IRESSA (gefitinib, ZD1839) Skip to content Home Media Press releases - 2005 - 2004 - 2003 - 2002 - 2001 - 2000 - 1999 - 1998 Corporate reports Facts, products, pipeline Image library Events calendar Media contacts Investors Careers Products Licensing Research Responsibility About us Contact us Home - - Media - - Press releases - -2003 - - function managePressContacts() { window.navigate("ncm.aspx?node=press");...
IRESSA (gefitinib) DEMONSTRATES CLINICAL ACTIVITY IN MULTIPLE TUMOUR TYPES Skip to content Home Media Press releases - 2005 - 2004 - 2003 - 2002 - 2001 - 2000 - 1999 - 1998 Corporate reports Facts, products, pipeline Image library Events calendar Media contacts Investors Careers Products Licensing Research Responsibility About us Contact us Home - - Media - - Press releases - -2003 - - function managePressContacts() { window.navigate("ncm.aspx?node=press");...
Iressa (gefitinib, ZD1839) - anti-cancer drug treats non-small-cell lung cancer (NSCLC) Skip to content Home Media Investors Careers Products Cardiovascular Gastrointestinal Infection Neuroscience Oncology Respiratory Non pharma businesses Licensing Research Responsibility About us Contact us Home - - Products - -Oncology - - Iressa (gefitinib, ZD1839) IRESSA (gefitinib, ZD1839) was the first in a new class of anti-cancer drugs known as epidermal growth factor receptor...
AstraZeneca Products - Drug information, prescription medicines, pharmaceuticals Skip to content Home Media Investors Careers Products Cardiovascular Gastrointestinal Infection Neuroscience Oncology Respiratory Non pharma businesses Licensing Research Responsibility About us Contact us Home - -Products - - Products Our skills and resources are concentrated on six important areas of healthcare - representing the majority of the worldwide burden of disease.
AstraZeneca Products - Drug information, prescription medicines, pharmaceuticals Skip to content Home Media Investors Careers Products Cardiovascular Gastrointestinal Infection Neuroscience Oncology Respiratory Non pharma businesses Licensing Research Responsibility About us Contact us Home - -Products - - Products Our skills and resources are concentrated on six important areas of healthcare - representing the majority of the worldwide burden of disease.
AstraZeneca Products - Oncology - Breast, lung, prostate and colorectal cancer treatments Skip to content Home Media Investors Careers Products Cardiovascular Gastrointestinal Infection Neuroscience Oncology Respiratory Non pharma businesses Licensing Research Responsibility About us Contact us Home - - Products - -Oncology - - Oncology Over 12 million people are diagnosed with cancer each year, and it is predicted to be the leading cause of death in the US by 2005.
AstraZeneca News - press release archive - pharmaceutical news - 2002 Skip to content Home Media Press releases - 2005 - 2004 - 2003 - 2002 - 2001 - 2000 - 1999 - 1998 Corporate reports Facts, products, pipeline Image library Events calendar Media contacts Investors Careers Products Licensing Research Responsibility About us Contact us Home - - Media - - Press releases - -2002 - - Press release archive 2002 19 December 2002 FDA ADVISORY COMMITTEE...
AstraZeneca News - press release archive - pharmaceutical news - 2003 Skip to content Home Media Press releases - 2005 - 2004 - 2003 - 2002 - 2001 - 2000 - 1999 - 1998 Corporate reports Facts, products, pipeline Image library Events calendar Media contacts Investors Careers Products Licensing Research Responsibility About us Contact us Home - - Media - - Press releases - -2003 - - Press release archive 2003 23 December 2003 EXANTAa„¢ ...
AstraZeneca Products - Drug information, prescription medicines, pharmaceuticals Skip to content Home Media Investors Careers Products Cardiovascular Gastrointestinal Infection Neuroscience Oncology Respiratory Non pharma businesses Licensing Research Responsibility About us Contact us Home - -Products - - Products Our skills and resources are concentrated on six important areas of healthcare - representing the majority of the worldwide burden of disease.
Results -- View - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
3rdWorld 80.3% for Not yet met; on- going imatinib leukemia (CML) IFN- alfa/ cytarabine study (estimated completion 2009) Gastrointestinal stromal 2/ 1/ 02 Novartis PR: 38% Not yet met; ongoing tumors (GIST) studies CML in blast crisis, 5/ 10/ 01 Novartis Hematologic response (chronic phase): 88% Met accelerated phase, or in Hematologic response (accelerated chronic phase after failure phase)...
author: tracy
subject: 3rdWorld
